证券日报网讯 1月12日，上海瀚讯（300762）在互动平台回答投资者提问时表示，公司始终坚持技术创 新驱动发展的战略，致力于通过不断夯实核心技术壁垒来提升市场综合竞争力，并保持对行业前沿动态 和客户需求的敏锐洞察；未来，公司将继续稳步推进既定发展规划，在深耕现有主营业务的同时，积极 寻求新兴领域的市场机遇，努力通过高质量的产品交付与服务争取更多业务机会，争取以更好的经营业 绩回报投资者。 ...

Core Viewpoint - CNOOC Engineering (海油工程) plans to acquire 49% of the shares of China Offshore Fluor Engineering (中海福陆) for 859 million yuan, aiming to enhance control and optimize management efficiency in the deepwater and new energy engineering sectors [1][2][3] Group 1: Acquisition Details - The acquisition will increase CNOOC Engineering's stake in China Offshore Fluor Engineering from 51% to 100%, allowing for full control [2][3] - The transaction price of 859 million yuan is significantly lower than the assessed value of approximately 4.017 billion yuan [3] - China Offshore Fluor Engineering reported a net profit of 50.81 million yuan for 2024 and 90.91 million yuan for the first three quarters of 2025, indicating strong financial performance [1][3] Group 2: Financial Performance - As of September 30, 2025, China Offshore Fluor Engineering had a net asset value of 4.046 billion yuan and projected revenues of 2.276 billion yuan for 2024 [3] - CNOOC Engineering's financial health is robust, with a debt-to-asset ratio of 39.35% as of September 2025, down from 41.38% at the end of 2024 [3] - The company has consistently increased its net profit, with figures of 854 million yuan, 1.237 billion yuan, 1.809 billion yuan, and 1.404 billion yuan from 2022 to the first three quarters of 2025 [5][6] Group 3: Research and Development - CNOOC Engineering has invested over 1 billion yuan in R&D annually from 2022 to 2024, totaling 4.317 billion yuan over four years [7] - In the first three quarters of 2025, R&D expenses increased by 21.93% to 782 million yuan despite a 13.54% decline in revenue [7] - The company focuses on technological innovation to drive growth, enhancing its capabilities in deepwater and new energy engineering [1][7] Group 4: Market Position and Orders - CNOOC Engineering is a leading contractor in the Asia-Pacific region for offshore oil and gas engineering, with a strong order backlog of approximately 59.5 billion yuan as of the third quarter of 2025 [6] - The company achieved a market contract value of 37.24 billion yuan in the first three quarters of 2025, a year-on-year increase of 124.85% [6]

Core Insights - Lunan Pharmaceutical Group has been recognized as the top company in the "Top 100 Innovative Private Enterprises" list for four consecutive years, showcasing its strong commitment to innovation in the pharmaceutical industry [1] - The company has accumulated over 2,800 patent authorizations and maintained a research and development investment intensity of over 10% for five consecutive years, establishing a robust innovation moat [1] Group 1: Innovation and Research - Lunan Pharmaceutical initiated a national key laboratory restructuring plan to integrate traditional Chinese medicine with modern pharmaceutical practices, overcoming industry challenges [2] - The company successfully developed a domestic culture medium that significantly reduced costs from 150 RMB per liter to 10 RMB, enabling the launch of a CD20 monoclonal antibody injection and breaking a 20-year foreign monopoly [3] - Lunan has established a research network with five national and eleven provincial platforms, collaborating with over 100 top global universities, resulting in an average of one new patent every three days [3] Group 2: Talent Strategy - The company employs a dual strategy of attracting global talent while cultivating local talent, ensuring a sustainable talent ecosystem [4] - The "Shennong Plan" and "Excellent Engineer Class" are key initiatives for recruiting top-tier talent, with competitive compensation packages and comprehensive research support [5] - The average age of the R&D team is 32, reflecting a youthful and dynamic workforce capable of handling over 40 clinical studies for new drugs [6] Group 3: Strategic Collaboration and Industry Impact - Lunan's innovation strategy has evolved from individual technological breakthroughs to a comprehensive restructuring of the industry chain, exemplified by the successful launch of the rituximab project [7] - The company has shared its breakthroughs in culture medium technology with eight local pharmaceutical companies, leading to an 18% reduction in overall production costs in Shandong [7] - Lunan Pharmaceutical has submitted over 40 active pharmaceutical ingredient registration applications in the U.S. and has 72 formulations approved in 129 countries, positioning its products prominently in international markets [8]